A Study to Assess the Effect of Rho-Kinase Inhibitor AR-1... | NCT02152774

Status Module

Description Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
0.5% Rho-Kinase Inhibitor	Experimental	AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.	Drug: Rho-Kinase Inhibitor
0.7% Rho-Kinase Inhibitor	Experimental	AR-12286 is a novel, potent Rho-kinase inhibitor developed by Aerie Pharmaceuticals, Inc., Bridgewater, NJ. It has single-digit nanomolar inhibitory activity against Rho-kinase in enzymatic inhibition assays. Mechanism-of action studies in monkeys demonstrate that AR-12286 lowers IOP primarily by increasing aqueous humor outflow through the trabecular meshwork Rho-kinase AR-12286 is well tolerated and produces clinically and statistically significant ocular hypotensive efficacy in patients with ocular hypertension and glaucoma. It is well tolerated by most patients and the only side effect was ocular hyperemia in a minority of subjects. It is currently in phase II testing.	Drug: Rho-Kinase Inhibitor

Name	Type	Description	Arm Group Labels	Other Names
Rho-Kinase Inhibitor	Drug		0.5% Rho-Kinase Inhibitor 0.7% Rho-Kinase Inhibitor

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Long Lasting effect of study drug to reduce IOP	To evaluate the ocular hypotensive efficacy of Rho kinase Inhibitor (AR-12286 0.5% and 0.7%) ophthalmic solutions in patients diagnosed with CACG treated for 6 months.	6 Months

Secondary Outcomes

Measure	Description	Time Frame
Secondary Outcome	To determine if AR-12286 can be used as directed therapy for CACG, reducing or eliminating the structural blockage of the trabecular meshwork that leads to development of elevated IOP.	6 Months

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Patients between 50 and 85 years old; of either sex.
Patients with CACG with ≥180⁰ PAS
IOP ≥22 mmHg prior to initiation of treatment in one or both eyes with two measurements taken two hours apart
No previous intraocular surgery except clear cornea phacoemulsification.
Corrected visual acuity in both eyes ≥20/50 in the eligible eye
Not more than 6 diopters spherical equivalent on the study eye
Not more than 3 diopters cylinder equivalent on the study eye
Have given written informed consent, prior to any investigational procedures.
Ability to attend for the 6-month duration of the study

Exclusion Criteria:

Open angle glaucoma
Closed angle glaucoma with <180⁰ PAS
Intraocular pressure >35 mmHg
Severe glaucomatous damage
Known hypersensitivity to any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics.
Previous intraocular surgery except clear cornea phacoemulsification.
Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study.
Ocular medication of any kind within 30 days of base-line visit, with the exception of ocular hypotensive medications and/or drops for treatment of dry eye syndrome (which may be used throughout the study).
Any abnormality preventing reliable applanation tonometry of either eye.
Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.
Changes of systemic medication that could have a substantial effect on IOP anticipated during the study.
Participation in any investigational study within the past 30 days.
Inability to perform reliable VF testing.
Unwilling to sign the consent form approved by the Institutional Review Board (IRB) of the New York Eye and Ear Infirmary.
Self-reported poor compliance to treatment.
Reluctance to return for scheduled follow-up visits.
Patients not able to understand the nature of the study.